secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019267
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss
---------------------------------------------------------------------------

- Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.
- Initiated PALISADE Phase 3 study of ARO-APOC3 in familial chylomicronemia syndrome; completed enrollment of 204 patients in Phase 2b ARCHES-2 for ARO-ANG3.
- Formed Visirna Therapeutics joint venture with Vivo Capital to expand into Greater China.
- Broke ground on new manufacturing facility; awarded up to $18.5M in tax incentives from Wisconsin and Verona.
- Total cash and investments of $603.5M as of March 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/0001564590-22-019267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/arwr-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer